Management and treatment optimization of patients with mild to moderate ulcerative colitis.
Fiche publication
Date publication
décembre 2023
Journal
Expert review of clinical immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
D'Amico F, Fasulo E, Jairath V, Paridaens K, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a significant health-care burden worldwide. While medical therapy aims to induce and maintain remission, optimal management of mild to moderate UC remains challenging due to heterogeneity in severity classifications and non-standardized approaches. This comprehensive review summarizes current evidence and knowledge gaps to optimize clinical decision-making in patients with mild to moderate UC.
Mots clés
5-ASA, Budesonide MMX, biomarkers, home testing, inflammatory bowel disease, optimization, quality of life, ulcerative colitis
Référence
Expert Rev Clin Immunol. 2023 12 7;: